RPR TAXOTERE JUNE LAUNCH LIKELY FOLLOWING ACCELERATED APPROVAL MAY 14; FIRM TO SUBMIT STUDIES OF TAXOTERE v. BRISTOL's TAXOL, DOXORUBICIN IN BREAST CANCER
Executive Summary
Rhone-Poulenc Rorer's second-line breast cancer therapy Taxotere (docetaxel) likely will be launched in June, the company indicates.